Filing Flows › Health Care › Fractyl Health (GUTS)
Fractyl Health (GUTS) earnings and revenue breakdown
Latest: Q4 2024 · 10-K filed Mar 3, 2025 · Fractyl Health (GUTS) Q4 2024 earnings results →
Q4 2024 Revenue down 57% year over year to $3K
Fractyl Health made $3K in Q4 2024 (-57% Y/Y). Operating margin n/m, net loss $25.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 3, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3K in Q4 2024, down 57% year over year and down 79% from the previous quarter.
Gross margin was 100.0%, up 28.6 points from a year earlier. Operating costs exceeded revenue by $25.2M, an operating margin of -840333.3%. Operating expenses grew 94% against a revenue fall of 57%. The fastest-growing cost line was Research & development (+99%). The quarter ended with a net loss of $25.0M, wider than the previous quarter's $23.2M loss.
Operating cash flow was −$17.0M. Non-cash charges added back $223K of depreciation and $2.9M of share-based compensation. Working capital and other items added $4.8M. Capital expenditures of $233K exceeded it, leaving free cash flow of −$17.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2024 | 10-K | Mar 3, 2025 | $3K | -57% | n/m | −$25.0M | −$17.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Fractyl Health
Fractyl is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
In its own words, from its 8-K, filed Aug 10, 2026.
Fractyl Health against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -57% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GUTS Fractyl Health | Q4 2024 | $3K | -57% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Fractyl Health 10-K on SEC EDGAR · CIK 1572616 · Surgical & Medical Instruments & Apparatus
More on GUTS
History
Every quarter: Q4 2024 results